Literature DB >> 33263720

Psychedelics in Psychiatry-Keeping the Renaissance From Going Off the Rails.

David B Yaden1,2, Mary E Yaden3, Roland R Griffiths1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33263720      PMCID： PMC8102315          DOI： 10.1001/jamapsychiatry.2020.3672

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN： 2168-622X            Impact factor:   21.596


× No keyword cloud information.
  7 in total

1.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

2.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Authors:  R R Griffiths; W A Richards; U McCann; R Jesse
Journal:  Psychopharmacology (Berl)       Date:  2006-07-07       Impact factor: 4.530

3.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

Review 4.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

5.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

6.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

7.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083
  7 in total
  15 in total

1.  The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy.

Authors:  Lisa A Page; Ahmad Rehman; Habib Syed; Kathryn Forcer; Graham Campbell
Journal:  Front Psychiatry       Date:  2021-11-26       Impact factor: 5.435

Review 2.  Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.

Authors:  David B Yaden; Dylan Earp; Marianna Graziosi; Dara Friedman-Wheeler; Jason B Luoma; Matthew W Johnson
Journal:  Front Psychol       Date:  2022-05-23

Review 3.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

Review 4.  N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.

Authors:  Edward James; Joachim Keppler; Thomas L Robertshaw; Ben Sessa
Journal:  Hum Psychopharmacol       Date:  2022-02-17       Impact factor: 2.130

5.  Legalization of Psychedelic Substances-Reply.

Authors:  William R Smith; Paul S Appelbaum
Journal:  JAMA       Date:  2021-12-21       Impact factor: 157.335

6.  Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.

Authors:  Victor Mocanu; Lindsay Mackay; Devon Christie; Elena Argento
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-05-14

Review 7.  Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.

Authors:  John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane
Journal:  Front Psychiatry       Date:  2021-12-17       Impact factor: 4.157

8.  Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems.

Authors:  Elena Argento; Devon Christie; Lindsay Mackay; Cody Callon; Zach Walsh
Journal:  Front Psychiatry       Date:  2021-09-06       Impact factor: 4.157

Review 9.  Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs.

Authors:  Enzo Tagliazucchi
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

10.  The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness.

Authors:  Morgan Campbell; Monnica T Williams
Journal:  Front Psychiatry       Date:  2021-07-05       Impact factor: 4.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.